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Myeloid-derived suppressor cells (MDSC) and regulatory
T cells (Treg) are major components of the immune sup-
pressive cells that potentially limit the effectiveness of an
immunotherapy-based treatment. Both of these suppres-
sive cell types have been shown to expand in tumor mod-
els and promote T-cell dysfunction that in turn favors
tumor progression. In preclinical studies using transplan-
table mouse models, we observed that live attenuated
bioengineered Listeria monocytogenes (Lm)-LLO immu-
notherapies have an impact on the suppressive ability of
MDSC and Treg in the tumor microenvironment (TME),
resulting in a loss in the ability of these cells to suppress
T cells. This alteration of immunosuppression in the
TME was an inherent property of all Lm-LLO immu-
notherapies tested and was independent of the tumor
model. The virtually total loss in the suppressive ability
of these cells in the TME was linked to a decrease in the
expression of arginase I in MDSC and IL-10 in Treg. We
are further investigating if the MDSC are differentiated
into functional macrophages that increase antigen pre-
sentation within the TME in order to stimulate T cell
immunity. Overall, this study provides insight into a
potentially novel mechanism of action of Lm-LLO immu-
notherapies that may contribute to therapeutic anti-
tumor responses.
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